Union Plans: Managing Rising Specialty Drug Costs

Important insights for anyone supporting labor and union funds. Staying ahead of these pipeline shifts — especially with specialty drugs driving such a large share of costs — is critical. Early awareness and proactive strategies make all the difference in protecting plan health.

The top 10 medications impacting pharmacy benefits in 2026 are set to reshape financial and clinical strategies for labor and union funds. Specialty drugs are less than two percent of prescriptions but drive over half of plan costs, presenting unique challenges for these groups. The 2026 pipeline highlights new anti-inflammatories, GLP-1s, and advanced therapies for complex and rare conditions. Early awareness and proactive management are key to controlling costs and supporting plan health. Learn more in the full article. https://rxbene.fit/4sTTrQ5 Union Labor Advisory Network #UnionStrong #PharmacyBenefits #HealthcareTrends

Pharmacy strategy and drug pricing dynamics continue to evolve quickly. This is a helpful breakdown of what employers should be paying attention to in 2026.

Public agencies across the country are looking for smarter ways to manage prescription drug costs without adding administrative burden. ArrayRx makes it possible to join a multi‑state pharmacy purchasing collaborative without a costly or time‑intensive RFP through an intergovernmental agreement (IGA). That means faster access to high‑value pharmacy solutions, stronger buying power and greater transparency in how tax dollars are spent. If your agency already has statutory authority to enter IGAs, you may be closer to savings than you think. #PublicSector #GovernmentEfficiency #PharmacyBenefits #IGA #TaxpayerStewardship #HealthcareCosts #PBM

Pharmacy strategy is getting more complex for employers. The U.S. drug pricing environment is shifting rapidly—and this time, the changes aren’t temporary. This year, drug pricing is being shaped by: 🏛️ State-by-state rules 📋 Increased PBM oversight ⚖️ Court decisions influencing timelines and enforcement For employers, this means: • More cost variability • More transparency — but also more complexity • Less predictability, more urgency to adapt Gallagher’s latest whitepaper, "The New Drug Pricing Reality: What Employers Must Know for 2026", breaks down what’s changing and why it matters https://lnkd.in/gxi_79GA #EmployeeBenefits #PharmacyBenefits #CostManagement

Pharmacy strategy is getting more complex for employers. The U.S. drug pricing environment is shifting rapidly—and this time, the changes aren’t temporary. This year, drug pricing is being shaped by: 🏛️ State-by-state rules 📋 Increased PBM oversight ⚖️ Court decisions influencing timelines and enforcement For employers, this means: • More cost variability • More transparency — but also more complexity • Less predictability, more urgency to adapt Gallagher’s latest whitepaper, "The New Drug Pricing Reality: What Employers Must Know for 2026", breaks down what’s changing and why it matters https://lnkd.in/gi9eAa3F #EmployeeBenefits #PharmacyBenefits #CostManagement

Pharmacy strategy is getting more complex for employers. The U.S. drug pricing environment is shifting rapidly—and this time, the changes aren’t temporary. This year, drug pricing is being shaped by: 🏛️ State-by-state rules 📋 Increased PBM oversight ⚖️ Court decisions influencing timelines and enforcement For employers, this means: • More cost variability • More transparency — but also more complexity • Less predictability, more urgency to adapt Gallagher’s latest whitepaper, "The New Drug Pricing Reality: What Employers Must Know for 2026", breaks down what’s changing and why it matters https://lnkd.in/dD6QrTCf #EmployeeBenefits #PharmacyBenefits #CostManagement

Pharmacy strategy is getting more complex for employers. The U.S. drug pricing environment is shifting rapidly—and this time, the changes aren’t temporary. This year, drug pricing is being shaped by: 🏛️ State-by-state rules 📋 Increased PBM oversight ⚖️ Court decisions influencing timelines and enforcement For employers, this means: • More cost variability • More transparency — but also more complexity • Less predictability, more urgency to adapt Gallagher’s latest whitepaper, "The New Drug Pricing Reality: What Employers Must Know for 2026", breaks down what’s changing and why it matters https://lnkd.in/d6zQs_b7 #EmployeeBenefits #PharmacyBenefits #CostManagement

Pharmacy strategy is getting more complex for employers. The U.S. drug pricing environment is shifting rapidly—and this time, the changes aren’t temporary. This year, drug pricing is being shaped by: 🏛️ State-by-state rules 📋 Increased PBM oversight ⚖️ Court decisions influencing timelines and enforcement For employers, this means: • More cost variability • More transparency — but also more complexity • Less predictability, more urgency to adapt Gallagher’s latest whitepaper, "The New Drug Pricing Reality: What Employers Must Know for 2026", breaks down what’s changing and why it matters https://lnkd.in/eiRGmqJX #EmployeeBenefits #PharmacyBenefits #CostManagement

Pharmacy strategy is getting more complex for employers. The U.S. drug pricing environment is shifting rapidly—and this time, the changes aren’t temporary. This year, drug pricing is being shaped by: 🏛️ State-by-state rules 📋 Increased PBM oversight ⚖️ Court decisions influencing timelines and enforcement For employers, this means: • More cost variability • More transparency — but also more complexity • Less predictability, more urgency to adapt Gallagher’s latest whitepaper, "The New Drug Pricing Reality: What Employers Must Know for 2026", breaks down what’s changing and why it matters https://lnkd.in/gJKyhm9E #EmployeeBenefits #PharmacyBenefits #CostManagement